• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

SLIDESHOW: Drug and Treatment Spotlights at Maui Derm NP+PA Fall


New and emerging therapies to treat a variety of skin conditions were presented by George Martin, MD, and Ted Rosen, MD.


1. Martin G, Rosen T. New drugs and new therapies for 2023. Presented at Maui Derm NP+PA Fall 2023; September 27-30, 2023; Asheville, NC.

2. Verrica Pharmaceuticals announces FDA approval of Ycanth (cantharidin) topical solution as the first FDA approved treatment of pediatric and adult patients with molluscum contagiosum. Verrica Pharmaceuticals. July 21, 2023. Accessed September 30, 2023. https://verrica.com/press_release/verrica-pharmaceuticals-announces-fda-approval-of-ycanth-cantharidin-topical-solution-0-7/

3. Browning JC, Enloe C, Cartwright M, et al. Efficacy and Safety of Topical Nitric Oxide-Releasing Berdazimer Gel in Patients With Molluscum Contagiosum: A Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2022;158(8):871-878. doi:10.1001/jamadermatol.2022.2721

4. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008;358(2):140-151. doi:10.1056/NEJMoa063564

5. Hoy SM. Baricitinib: a review in moderate to severe atopic dermatitis [published correction appears in Am J Clin Dermatol. 2022 Sep;23(5):747]. Am J Clin Dermatol. 2022;23(3):409-420. doi:10.1007/s40257-022-00684-1

6. Paller AS, Flohr C, Cork M, et al. Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial [published correction appears in JAMA Dermatol. 2023 Jun 1;159(6):673]. JAMA Dermatol. 2023;159(6):596-605. doi:10.1001/jamadermatol.2023.0627

7. Yosipovitch G, Mollanazar N, Ständer S, et al. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. Nat Med. 2023;29(5):1180-1190. doi:10.1038/s41591-023-02320-9

8. Maurer M, Casale T, Saini S, et al. Dupilumab significantly reduces itch and hives in patients with chronic spontaneous urticaria: results from a phase 3 trial (LIBERTY-CSU CUPID Study A). Journal of Allergy and Clinical Immunology. 2022;149(2). doi:10.1016/j.jaci.2021.12.002

9. RECELL Autologous Cell Harvesting Device (model number: AVRL0102). U.S. Food and Drug Administration. Published June 22, 2023. Accessed October 1, 2023. https://www.fda.gov/vaccines-blood-biologics/recell-autologous-cell-harvesting-device-model-number-avrl0102.

10. Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. 2023;401(10378):747-761. doi:10.1016/S0140-6736(23)00022-3

Related Videos
© 2024 MJH Life Sciences

All rights reserved.